These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22393940)

  • 1. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.
    Zhang W; Fujii N; Naren AP
    Future Med Chem; 2012 Mar; 4(3):329-45. PubMed ID: 22393940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.
    Zhang W; Zhang Z; Zhang Y; Naren AP
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28869532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
    Verkman AS; Lukacs GL; Galietta LJ
    Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR pharmacology and its role in intestinal fluid secretion.
    Thiagarajah JR; Verkman AS
    Curr Opin Pharmacol; 2003 Dec; 3(6):594-9. PubMed ID: 14644010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CFTR pharmacology.
    Zegarra-Moran O; Galietta LJ
    Cell Mol Life Sci; 2017 Jan; 74(1):117-128. PubMed ID: 27704174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.
    Li C; Naren AP
    Pharmacol Ther; 2005 Nov; 108(2):208-23. PubMed ID: 15936089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CFTR inhibitors.
    Verkman AS; Synder D; Tradtrantip L; Thiagarajah JR; Anderson MO
    Curr Pharm Des; 2013; 19(19):3529-41. PubMed ID: 23331030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.
    Cil O; Phuan PW; Gillespie AM; Lee S; Tradtrantip L; Yin J; Tse M; Zachos NC; Lin R; Donowitz M; Verkman AS
    FASEB J; 2017 Feb; 31(2):751-760. PubMed ID: 27871064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New horizons in the treatment of cystic fibrosis.
    Cuthbert AW
    Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel.
    Smith E; Giuliano KA; Shumate J; Baillargeon P; McEwan B; Cullen MD; Miller JP; Drew L; Scampavia L; Spicer TP
    Assay Drug Dev Technol; 2017 Dec; 15(8):395-406. PubMed ID: 29172645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and development of antisecretory drugs for treating diarrheal diseases.
    Thiagarajah JR; Ko EA; Tradtrantip L; Donowitz M; Verkman AS
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):204-9. PubMed ID: 24316107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CFTR inhibitors for treating diarrheal disease.
    Thiagarajah JR; Verkman AS
    Clin Pharmacol Ther; 2012 Sep; 92(3):287-90. PubMed ID: 22850599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced secretory diarrhea: A role for CFTR.
    Moon C; Zhang W; Sundaram N; Yarlagadda S; Reddy VS; Arora K; Helmrath MA; Naren AP
    Pharmacol Res; 2015 Dec; 102():107-112. PubMed ID: 26429773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chloride channel-targeted therapy for secretory diarrheas.
    Thiagarajah JR; Verkman AS
    Curr Opin Pharmacol; 2013 Dec; 13(6):888-94. PubMed ID: 23992767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid therapeutic advances in CFTR modulator science.
    Clancy JP
    Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
    Mall MA; Mayer-Hamblett N; Rowe SM
    Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.